KYTHERA Biopharmaceuticals Receives New Coverage from Analysts at FBR Capital Markets (KYTH)
FBR Capital Markets initiated coverage on shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) in a research note issued on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $58.00 price target on the stock. FBR Capital Markets’ price target would suggest a potential upside of 30.04% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Bank of America Corp. initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Friday, October 25th. They set a “buy” rating on the stock. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of KYTHERA Biopharmaceuticals from $34.00 to $45.00 in a research note to investors on Tuesday, September 17th. They now have an “overweight” rating on the stock. Finally, analysts at Cowen and Company reiterated a “buy” rating on shares of KYTHERA Biopharmaceuticals in a research note to investors on Tuesday, September 17th. They now have a $50.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $45.33.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) opened at 44.60 on Wednesday. KYTHERA Biopharmaceuticals has a 52 week low of $14.07 and a 52 week high of $47.85. The stock’s 50-day moving average is $43.79 and its 200-day moving average is $29.99. The company’s market cap is $947.6 million.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last announced its earnings results on Tuesday, August 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.03. Analysts expect that KYTHERA Biopharmaceuticals will post $-2.89 EPS for the current fiscal year.
KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.